1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
02/27/2024 | CLDX | Buy Now | Celldex Therapeutics | $40.96 | 119.73% | Guggenheim | Yatin Suneja | $72 → $90 | Maintains | Buy | Get Alert |
12/20/2023 | CLDX | Buy Now | Celldex Therapeutics | $40.96 | — | TD Cowen | Yaron Werber | — | Initiates | → Outperform | Get Alert |
11/10/2023 | CLDX | Buy Now | Celldex Therapeutics | $40.96 | -34.08% | Wells Fargo | Derek Archila | → $27 | Upgrade | Underweight → Equal-Weight | Get Alert |
11/06/2023 | CLDX | Buy Now | Celldex Therapeutics | $40.96 | 95.31% | HC Wainwright & Co. | Joseph Pantginis | $73 → $80 | Maintains | Buy | Get Alert |
11/03/2023 | CLDX | Buy Now | Celldex Therapeutics | $40.96 | 26.95% | Cantor Fitzgerald | Kristen Kluska | $54 → $52 | Maintains | Overweight | Get Alert |
10/12/2023 | CLDX | Buy Now | Celldex Therapeutics | $40.96 | 31.84% | Cantor Fitzgerald | Kristen Kluska | → $54 | Reiterates | Overweight → Overweight | Get Alert |
09/27/2023 | CLDX | Buy Now | Celldex Therapeutics | $40.96 | 31.84% | Cantor Fitzgerald | Kristen Kluska | → $54 | Reiterates | Overweight → Overweight | Get Alert |
08/22/2023 | CLDX | Buy Now | Celldex Therapeutics | $40.96 | -48.73% | Wells Fargo | Derek Archila | → $21 | Initiates | → Underweight | Get Alert |
08/16/2023 | CLDX | Buy Now | Celldex Therapeutics | $40.96 | 31.84% | Cantor Fitzgerald | Kristen Kluska | → $54 | Reiterates | Overweight → Overweight | Get Alert |
08/10/2023 | CLDX | Buy Now | Celldex Therapeutics | $40.96 | 78.22% | HC Wainwright & Co. | Joseph Pantginis | → $73 | Reiterates | Buy → Buy | Get Alert |
08/09/2023 | CLDX | Buy Now | Celldex Therapeutics | $40.96 | 78.22% | HC Wainwright & Co. | Joseph Pantginis | → $73 | Reiterates | Buy → Buy | Get Alert |
06/12/2023 | CLDX | Buy Now | Celldex Therapeutics | $40.96 | 78.22% | HC Wainwright & Co. | Joseph Pantginis | → $73 | Reiterates | Buy → Buy | Get Alert |
05/31/2023 | CLDX | Buy Now | Celldex Therapeutics | $40.96 | 78.22% | HC Wainwright & Co. | Joseph Pantginis | → $73 | Reiterates | → Buy | Get Alert |
05/05/2023 | CLDX | Buy Now | Celldex Therapeutics | $40.96 | 31.84% | Cantor Fitzgerald | Kristen Kluska | $55 → $54 | Maintains | Overweight | Get Alert |
05/05/2023 | CLDX | Buy Now | Celldex Therapeutics | $40.96 | 78.22% | HC Wainwright & Co. | Joseph Pantginis | → $73 | Reiterates | → Buy | Get Alert |
03/22/2023 | CLDX | Buy Now | Celldex Therapeutics | $40.96 | 78.22% | HC Wainwright & Co. | Joseph Pantginis | → $73 | Reiterates | → Buy | Get Alert |
03/01/2023 | CLDX | Buy Now | Celldex Therapeutics | $40.96 | 78.22% | HC Wainwright & Co. | Joseph Pantginis | → $73 | Reiterates | → Buy | Get Alert |
02/27/2023 | CLDX | Buy Now | Celldex Therapeutics | $40.96 | 78.22% | HC Wainwright & Co. | Joseph Pantginis | → $73 | Reiterates | → Buy | Get Alert |
11/11/2022 | CLDX | Buy Now | Celldex Therapeutics | $40.96 | 53.81% | Guggenheim | Yatin Suneja | $68 → $63 | Maintains | Buy | Get Alert |
The latest price target for Celldex Therapeutics (NASDAQ: CLDX) was reported by Guggenheim on February 27, 2024. The analyst firm set a price target for $90.00 expecting CLDX to rise to within 12 months (a possible 119.73% upside). 16 analyst firms have reported ratings in the last year.
The latest analyst rating for Celldex Therapeutics (NASDAQ: CLDX) was provided by Guggenheim, and Celldex Therapeutics maintained their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Celldex Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Celldex Therapeutics was filed on February 27, 2024 so you should expect the next rating to be made available sometime around February 27, 2025.
While ratings are subjective and will change, the latest Celldex Therapeutics (CLDX) rating was a maintained with a price target of $72.00 to $90.00. The current price Celldex Therapeutics (CLDX) is trading at is $40.96, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.